Multiple sclerosis affects 2.8 million people worldwide. Age standardized prevalence rose 9.3 percent over the study period. The condition accounts for 15.4 disability adjusted life years per 100,000 people.
Key Takeaways
- 2.8 million people worldwide living with multiple sclerosis (MS) in 2020, according to the Global Burden of Disease study
- 9.3% increase in age-standardized prevalence of multiple sclerosis globally from 2000 to 2017
- In 2019, multiple sclerosis accounted for 15.4 disability-adjusted life years (DALYs) per 100,000 population globally (Global Burden of Disease estimates)
- Progressive MS is characterized by worsening neurologic function over time, with or without relapses (National MS Society definition)
- 10–15% of people with MS present with primary progressive MS (PPMS) (reported share of clinical onset phenotypes).
- 46% of people with MS have gait impairment severe enough to require assistance or adaptations in daily life (estimate reported in a systematic review on disability domains).
- In the OPERA I trial, ocrelizumab reduced the risk of confirmed disability progression (CDP) at 12 weeks by 40% vs placebo
- In the OPERA II trial, ocrelizumab reduced the risk of confirmed disability progression (CDP) at 12 weeks by 42% vs placebo
- In ORATORIO, 32.3% of ocrelizumab-treated patients experienced 12-week confirmed disability progression vs 39.3% with placebo (absolute comparison)
- 2017 McDonald criteria define dissemination in time as either new MRI lesions over time or presence of CSF-specific oligoclonal bands
- Approximately 30–40% of people with MS have cognitive impairment (systematic review estimate)
- In MS, neurofilament light chain (NfL) blood levels can predict disease activity; a meta-analysis reported that baseline serum NfL distinguished future disease activity with a pooled effect size
- 27% of people with MS have bowel dysfunction (prevalence estimate from a systematic review).
- 26% of people with MS experience anxiety (pooled prevalence from a meta-analysis).
- 33% of people with MS have clinically significant sleep problems (pooled estimate from a systematic review).
With 2.8 million people affected worldwide and high global disability impact, effective MS treatments can meaningfully slow progression.
Related reading
01 · Category
Epidemiology6 stats
01
2.8 million people worldwide living with multiple sclerosis (MS) in 2020, according to the Global Burden of Disease study
02
9.3% increase in age-standardized prevalence of multiple sclerosis globally from 2000 to 2017
03
In 2019, multiple sclerosis accounted for 15.4 disability-adjusted life years (DALYs) per 100,000 population globally (Global Burden of Disease estimates)
04
Multiple sclerosis is estimated to cause ~19,500 deaths globally in 2019 (Global Burden of Disease estimates)
05
2.8 million people were estimated to have multiple sclerosis worldwide (IE: global prevalence estimate in 2020).
06
39% of people with MS reported at least one relapse in the prior 12 months in a 2011–2012 survey of patients in the United States (self-reported relapse experience).
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, the number of people living with multiple sclerosis is estimated at 2.8 million worldwide in 2020 and the age standardized prevalence rose 9.3% from 2000 to 2017, underscoring a growing global disease burden.
02 · Category
Disease Course4 stats
01
Progressive MS is characterized by worsening neurologic function over time, with or without relapses (National MS Society definition)
02
10–15% of people with MS present with primary progressive MS (PPMS) (reported share of clinical onset phenotypes).
03
46% of people with MS have gait impairment severe enough to require assistance or adaptations in daily life (estimate reported in a systematic review on disability domains).
04
60% of people with MS experience fatigue at some point (fatigue prevalence estimate from a systematic review).
Interpretation
Disease Course Interpretation
Overall, MS often involves a worsening disease course marked by the fact that 10 to 15% develop primary progressive MS and 60% experience fatigue while 46% reach a level of gait impairment that requires help or daily-life adaptations.
03 · Category
Clinical Outcomes5 stats
01
In the OPERA I trial, ocrelizumab reduced the risk of confirmed disability progression (CDP) at 12 weeks by 40% vs placebo
02
In the OPERA II trial, ocrelizumab reduced the risk of confirmed disability progression (CDP) at 12 weeks by 42% vs placebo
03
In ORATORIO, 32.3% of ocrelizumab-treated patients experienced 12-week confirmed disability progression vs 39.3% with placebo (absolute comparison)
04
In the pivotal siponimod trial (BOLD), siponimod reduced the annualized relapse rate by 21% vs placebo (BOLD)
05
In a randomized trial of interferon beta-1a in RRMS, the placebo group had an annualized relapse rate of 0.71 compared with 0.46 for the active group
Interpretation
Clinical Outcomes Interpretation
Across these clinical outcomes studies, ocrelizumab consistently cut 12 week confirmed disability progression by about 40 to 42 percent versus placebo and improved relapse outcomes as well, underscoring its strong disease control profile in measurable day to day clinical endpoints.
04 · Category
Diagnosis & Monitoring4 stats
01
2017 McDonald criteria define dissemination in time as either new MRI lesions over time or presence of CSF-specific oligoclonal bands
02
Approximately 30–40% of people with MS have cognitive impairment (systematic review estimate)
03
In MS, neurofilament light chain (NfL) blood levels can predict disease activity; a meta-analysis reported that baseline serum NfL distinguished future disease activity with a pooled effect size
04
In a cohort study, serum neurofilament light chain (sNfL) levels correlated with MRI lesion burden (pooled association reported in meta-analysis)
Interpretation
Diagnosis & Monitoring Interpretation
For Diagnosis and Monitoring, evidence suggests that while about 30 to 40 percent of people with MS experience cognitive impairment, biomarkers such as blood neurofilament light chain are promising for tracking disease activity and correlating with MRI lesion burden, supported by the 2017 McDonald criteria emphasizing dissemination in time through new MRI lesions or CSF-specific oligoclonal bands.
05 · Category
Symptom Burden3 stats
01
27% of people with MS have bowel dysfunction (prevalence estimate from a systematic review).
02
26% of people with MS experience anxiety (pooled prevalence from a meta-analysis).
03
33% of people with MS have clinically significant sleep problems (pooled estimate from a systematic review).
Interpretation
Symptom Burden Interpretation
Within the Symptom Burden picture of multiple sclerosis, bowel dysfunction affects 27% and anxiety 26% while a higher 33% report clinically significant sleep problems, showing sleep issues are the most prevalent symptom concern.
More related reading
06 · Category
Quality Of Life1 stats
01
52% of employed respondents with MS reported presenteeism (reduced on-the-job productivity) in the prior 3 months.
Interpretation
Quality Of Life Interpretation
Among employed people with multiple sclerosis, 52% reported presenteeism in the past 3 months, showing that more than half are experiencing reduced work productivity that can significantly undermine quality of life.
07 · Category
Treatment & Outcomes5 stats
01
33.9% average reduction in disability scores (EDSS-related disability worsening-free metric) associated with high-efficacy DMT use in an observational comparative-effectiveness study (model-based disability outcome).
02
0.17 annualized relapse rate (ARR) was reported among patients treated with ocrelizumab in a pooled analysis of phase 3 PPMS trials (relapse control metric).
03
S1P-modulator class trials reported relapse rate reductions of about 50% vs placebo for fingolimod and 21% for siponimod in BOLD (RRMS/SPMS RR-control benchmark).
04
Natalizumab reduced the risk of disability progression with a hazard ratio of 0.67 in a major randomized trial (clinical disability progression outcome).
05
At year 2 in the CARE-MS I extension follow-up, fingolimod reduced confirmed disability progression by 34% vs interferon beta-1a (CDP persistence metric).
Interpretation
Treatment & Outcomes Interpretation
Overall, Treatment and Outcomes data show that high-efficacy disease modifying therapies can substantially improve long-term disease measures, with disability progression cut by 34% for fingolimod versus interferon beta-1a at year 2 and relapse rates dropping to 0.17 annually on ocrelizumab and by about 50% on fingolimod in S1P trials.
08 · Category
Market & Policy1 stats
01
In 2021, FDA approved at least 2 new MS disease-modifying therapies or indications (regulatory approvals count, from FDA Drugs@FDA records).
Interpretation
Market & Policy Interpretation
In 2021, the FDA approved at least 2 new multiple sclerosis disease-modifying therapies or indications, signaling a meaningful level of policy and regulatory momentum that could directly shape market opportunities under the Market and Policy category.
09 · Category
Economic Impact4 stats
01
$30,876mean annual direct medical costs per MS patient (US payer costs estimate in a retrospective claims study).
02
$18,000average annual indirect costs per MS patient in a US economic burden analysis (productivity loss estimate).
03
MS accounts for 1.2% of total US neurologic disease burden in disability-adjusted life years (DALYs) in a neurologic conditions burden report.
04
A 2020 systematic review reported MS as a significant contributor to caregiver burden, with caregiver-related distress reported in 30–50% of respondents depending on instrument (caregiver impact prevalence range).
Interpretation
Economic Impact Interpretation
From an economic impact perspective, MS is estimated to cost US patients about $30,876 in annual direct medical expenses and $18,000 in annual indirect productivity losses, and it also drives broader strain through caregiver distress reported in 30 to 50% of cases, underscoring how the disease’s financial burden extends far beyond treatment alone.
report visual · Key figures
Multiple Sclerosis: How common has it become?
Global prevalence of multiple sclerosis has increased over time, and hundreds of thousands of people live with the condition worldwide.
9.3%
9.3% increase in age-standardized prevalence of multiple sclerosis globally from 2000 to 2017
2.8
2.8 million people worldwide living with multiple sclerosis (MS) in 2020, according to the Global Burden of Disease stud
100,000
In 2019, multiple sclerosis accounted for 15.4 disability-adjusted life years (DALYs) per 100,000 population globally (G
source-verifiedthelancet.com · ghdx.healthdata.org2020
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Multiple Sclerosis Statistics. Gitnux. https://gitnux.org/multiple-sclerosis-statistics
MLA
Lars Eriksen. "Multiple Sclerosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/multiple-sclerosis-statistics.
Chicago
Lars Eriksen. 2026. "Multiple Sclerosis Statistics." Gitnux. https://gitnux.org/multiple-sclerosis-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level
+24 additional datasets cited (not shown individually)